In development: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Guidance programme 1 selected

Guidance programme

Area of interest

Showing 126 to 150 of 302

TitleTypeExpected publication date
Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]Technology appraisal guidanceTBC
Ixekizumab for treating enthesitis-related arthritis and juvenile psoriatic arthritis in people 2 to 17 years [ID6590]Technology appraisal guidanceTBC
Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]Technology appraisal guidanceTBC
Larotrectinib for treating NTRK fusion-positive advanced solid tumours (MA review of TA630) [ID6292]Technology appraisal guidance
Lecanemab for treating mild cognitive impairment or mild dementia caused by Alzheimer's disease [ID4043]Technology appraisal guidanceTBC
Lenacapavir for preventing HIV-1 in people aged 16 years or older [ID6495]Technology appraisal guidanceTBC
Lenadogene nolparvovec for treating Leber's hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]Technology appraisal guidanceTBC
Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]Technology appraisal guidanceTBC
Leriglitazone for treating cerebral adrenoleukodystrophy in people 2 years and over [ID3903]Technology appraisal guidanceTBC
Leukocyte interleukin in combination for neoadjuvant treatment of resectable locally advanced squamous cell head and neck cancer [ID6390]Technology appraisal guidanceTBC
Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]Technology appraisal guidanceTBC
Linvoseltamab for treating relapsed or refractory multiple myeloma after 3 or more treatments [ID6609]Technology appraisal guidance
Lisocabtagene maraleucel for treating relapsed or refractory large B-cell lymphoma after 2 or more lines of systemic treatment (review of TA987) [ID6619]Technology appraisal guidance
Low-dose atropine eye drops for treating myopia in people 3 to 14 years [ID6517]Technology appraisal guidance
Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]Technology appraisal guidanceTBC
Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced platinum-resistant ovarian cancer [ID1340]Technology appraisal guidanceTBC
Lurbinectedin for treating advanced small-cell lung cancer on or after platinum-based chemotherapy [ID3872]Technology appraisal guidanceTBC
Lurbinectedin with atezolizumab for maintenance treatment of extensive-stage small-cell lung cancer [ID6526]Technology appraisal guidance
Lutetium oxodotreotide with octreotide for newly diagnosed unresectable or metastatic gastroenteropancreatic neuroendocrine tumours [ID6315]Technology appraisal guidanceTBC
Lutetium-177 vipivotide tetraxetan in combination for treating PSMA-positive hormone-sensitive metastatic prostate cancer [ID6589]Technology appraisal guidanceTBC
Maralixibat for treating cholestatic pruritus in Alagille syndrome [ID3941]Technology appraisal guidanceTBC
Maralixibat for treating progressive familial intrahepatic cholestasis [ID3818]Technology appraisal guidanceTBC
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]Technology appraisal guidanceTBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All